A plain-language guide

mast cell activation syndrome

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Growing map · 36 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. mast cell activation syndrome is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's mast cell activation syndrome?

Mast cell activation syndrome is a condition in which mast cells release their chemical mediators inappropriately, causing recurring symptoms across several body systems. Under the widely used consensus criteria it is diagnosed only when three things are met together: typical recurrent symptoms of mast cell mediator release, an objective rise in blood tryptase during an episode (at least 20% above the person's own baseline plus 2 ng/mL), and improvement on medicines that block or stabilise mast cells.

Also indexed asMONDO:0100004
Features mapped7
Treatments mapped8
Published sources8
Last reviewed2026-08-04

Signs and symptoms

Urticaria

Hives (urticaria) are a common skin sign during episodes of mast cell mediator release.

Limited evidenceSource: PMID:42149735
Evidence ratingweak
Study designcohort
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:42149735 via curation 2026-06-12.
Last reviewed2026-06-12

Angioedema

Deeper swelling of the skin (angioedema), often around the face or lips, can occur during episodes.

Limited evidenceSource: PMID:42149735
Evidence ratingweak
Study designcohort
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:42149735 via curation 2026-06-12.
Last reviewed2026-06-12

Flushing

Sudden flushing, a warm reddening of the skin, is a characteristic feature of mast cell mediator release.

Limited evidenceSource: PMID:42149735
Evidence ratingweak
Study designcohort
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:42149735 via curation 2026-06-12.
Last reviewed2026-06-12

Pruritus

Itching (pruritus) is a frequent skin symptom during episodes.

Limited evidenceSource: PMID:42149735
Evidence ratingweak
Study designcohort
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:42149735 via curation 2026-06-12.
Last reviewed2026-06-12

Gastrointestinal symptoms

The gut is commonly involved, with symptoms such as cramping, nausea, and diarrhoea during episodes.

Limited evidenceSource: PMID:42149735
Evidence ratingweak
Study designcohort
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:42149735 via curation 2026-06-12.
Last reviewed2026-06-12

Recurrent anaphylaxis

Some people have recurrent anaphylaxis, severe whole-body allergic-type reactions, often without an identifiable allergy.

Limited evidenceSource: PMID:42149735
Evidence ratingweak
Study designcohort
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:42149735 via curation 2026-06-12.
Last reviewed2026-06-12

Transient rise in serum tryptase

A temporary rise in blood tryptase during a symptom flare, at least 20% above the person's baseline plus 2 ng/mL, is the objective marker used to confirm that mast cells are activating.

Limited evidenceSource: PMID:42149735
Evidence ratingweak
Study designcohort
Confidence (0-1)0.7
Replicationunreplicated
Notesplain_language confirmed from PMID:42149735 via curation 2026-06-12.
Last reviewed2026-06-12

How it is diagnosed

Mast cell activation syndrome

Diagnosed using: Hypotension.

Limited evidenceSource: PMID:38948000
The source text this rests on
“For instance, mast cell activation syndrome is known as an augmented number of cells due to decreased cell death, resulting in clinical symptoms affecting many systems. The main common symptoms include flushing, hypotension, urticaria, angioedema, headache, vomiting and diarrhea.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:38948000 via curation 2026-06-24
Last reviewed2026-06-24

Mast cell activation syndrome

Diagnosed using: Headache.

Limited evidenceSource: PMID:38948000
The source text this rests on
“For instance, mast cell activation syndrome is known as an augmented number of cells due to decreased cell death, resulting in clinical symptoms affecting many systems. The main common symptoms include flushing, hypotension, urticaria, angioedema, headache, vomiting and diarrhea.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:38948000 via curation 2026-06-24
Last reviewed2026-06-24

Mast cell activation syndrome

Diagnosed using: Serum tryptase 20% plus 2 criterion.

Limited evidenceSource: PMID:42149735
The source text this rests on
“MCAD encompasses MCA syndrome (MCAS) which is defined by (i) documented systemic symptoms of MCA, (ii) a 20% increase in serum tryptase level from the individual's baseline plus 2 ng/mL and (iii) a symptom response to MC-stabilizing drugs.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:42149735 via curation 2026-06-24
Last reviewed2026-06-24

Mast cell activation syndrome

Diagnosed using: Episodic multisystem symptoms.

Limited evidenceSource: PMID:41272881
The source text this rests on
“Symptoms should be severe, episodic, typical of mast cell activation, and involve at least two organ systems.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41272881 via curation 2026-06-24
Last reviewed2026-06-24

Mast cell activation syndrome

Diagnosed using: Consensus diagnostic criteria.

Limited evidenceSource: PMID:38243020
The source text this rests on
“MCAS is characterized by the presence of typical clinical symptoms, a substantial elevation in serum tryptase levels during an attack compared to the patient's baseline tryptase levels, and a response to MC mediator-targeting therapy.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:38243020 via curation 2026-06-24
Last reviewed2026-06-24

Mast cell activation syndrome

Diagnosed using: 24-hour urinary mast cell mediators.

Limited evidenceSource: PMID:25439370
The source text this rests on
“We recommend measurement of 24-hour urine 11β-PGF₂α and serum tryptase levels of patients with symptoms suggestive of MCAS.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:25439370 via curation 2026-06-25
Last reviewed2026-06-25

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

H1/H2 antihistamines

H1 and H2 antihistamines, which block the effects of histamine released by mast cells, are a first-line treatment and often reduce symptoms substantially; a response to mast-cell-targeting medicines is itself part of the diagnostic criteria.

Used to help with: Mast cell activation syndrome.

Limited evidenceSource: PMID:42149735
The source text this rests on
“The administration of H1 and/or H2 antihistamines drugs +/- a leukotriene receptor antagonist resulted in a marked reduction in symptoms.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:42149735 via curation 2026-06-12
Last reviewed2026-06-12

Mast cell stabilizers

Mast cell stabilizers are one class of medication used when mast cell activation syndrome is suspected, alongside histamine receptor antagonists.

Used to help with: Mast cell activation syndrome.

Limited evidenceSource: PMID:40387691
The source text this rests on
“When MCAS is suspected, patients can benefit from treatment with histamine receptor antagonists and/or mast cell stabilizers, in addition to avoiding triggers such as certain foods, alcohol, strong smells, temperature changes, mechanical stimuli (eg, friction), emotional…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40387691 via curation 2026-06-24
Last reviewed2026-06-24

Trigger avoidance

Avoiding triggers such as certain foods, alcohol, strong smells, temperature changes, mechanical stimuli, and emotional distress is part of managing mast cell activation syndrome.

Used to help with: Mast cell activation syndrome.

Limited evidenceSource: PMID:40387691
The source text this rests on
“When MCAS is suspected, patients can benefit from treatment with histamine receptor antagonists and/or mast cell stabilizers, in addition to avoiding triggers such as certain foods, alcohol, strong smells, temperature changes, mechanical stimuli (eg, friction), emotional…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40387691 via curation 2026-06-24
Last reviewed2026-06-24

Omalizumab

Omalizumab can reduce mast cell mediator-related symptoms in people with mast cell activation syndrome that does not respond to standard therapy.

Used to help with: Mast cell activation syndrome.

Limited evidenceSource: PMID:39741373
The source text this rests on
“The majority of patients with refractory MCAS reported in the literature had a reduction in mast cell mediator-related symptoms with the addition of omalizumab.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:39741373 via curation 2026-06-24
Last reviewed2026-06-24

epinephrine auto-injector

An epinephrine auto-injector is used to treat acute episodes of mast cell activation syndrome, particularly when the reaction meets anaphylaxis criteria.

Used to help with: Mast cell activation syndrome.

Limited evidenceSource: PMID:41272881
The source text this rests on
“Management includes instructing patients to treat acute episodes with an epinephrine auto-injector, particularly when anaphylaxis criteria are met.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41272881 via curation 2026-06-25
Last reviewed2026-06-25

leukotriene receptor antagonist

A leukotriene receptor antagonist can be added to H1 and/or H2 antihistamines for mast cell activation syndrome; in a pediatric-onset cohort, this combination was associated with a marked reduction in symptoms.

Used to help with: Mast cell activation syndrome.

Limited evidenceSource: PMID:42149735
The source text this rests on
“The administration of H1 and/or H2 antihistamines drugs +/- a leukotriene receptor antagonist resulted in a marked reduction in symptoms.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:42149735 via curation 2026-06-25
Last reviewed2026-06-25

cromolyn sodium

Cromolyn sodium, an oral mast cell stabilizer, has been reported to help control signs and symptoms of mast cell activation in people with mast cell activation syndrome.

Used to help with: Mast cell activation syndrome.

Limited evidenceSource: PMID:41728426
The source text this rests on
“…a cromolyn dose of 1600-2400 mg daily, administered using the continuous oral dosing regimen during the day, was effective in controlling signs and symptoms of mast cell activation.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41728426 via curation 2026-06-25
Last reviewed2026-06-25

aspirin

Aspirin therapy may be used in mast cell activation syndrome for people who have raised levels of the urinary mast cell mediator 11β-PGF₂α, a marker linked with flushing.

Used to help with: Mast cell activation syndrome.

Limited evidenceSource: PMID:25439370
The source text this rests on
“We recommend aspirin therapy for patients with MCAS and with elevated 24-hour urine 11β-PGF₂α levels.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:25439370 via curation 2026-06-25
Last reviewed2026-06-25

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 8 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

PMID:25439370 · Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11
PMID:38243020 · Using the Right Criteria for MCAS.
PMID:38948000 · Mast cell activation syndrome: An up-to-date review of literature.
PMID:39741373 · Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome.
PMID:40387691 · AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndr
PMID:41272881 · Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach.
PMID:41728426 · A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue S
PMID:42149735 · Characteristics and outcomes of patients with pediatric-onset non-mastocytosis mast cell activation disorders

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.